SevenBridge Financial Group LLC Reduces Position in Amgen Inc. $AMGN

SevenBridge Financial Group LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 24.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,459 shares of the medical research company’s stock after selling 2,689 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Amgen were worth $2,387,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after buying an additional 165,281 shares during the last quarter. State Street Corp lifted its holdings in shares of Amgen by 0.6% in the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after buying an additional 177,035 shares during the period. Capital International Investors boosted its stake in shares of Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors raised its position in Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Amgen by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after purchasing an additional 291,271 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AMGN. Barclays started coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Cantor Fitzgerald increased their target price on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Guggenheim boosted their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Finally, Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $354.00.

Amgen Price Performance

Amgen stock opened at $377.64 on Thursday. The company has a fifty day simple moving average of $356.15 and a 200-day simple moving average of $324.33. The firm has a market capitalization of $203.57 billion, a price-to-earnings ratio of 26.54, a PEG ratio of 3.72 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.